mRNA Adjuvant Sequences for Vaccine Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mRNA vaccines face challenges in generating robust and sustained protective immunity due to insufficient innate immune stimulation, requiring additional adjuvants that can lead to off-target effects and complex delivery methods.
Innovation Solution
An in vitro-transcribed mRNA vaccine platform that combines a protein-coding sequence and an immunostimulatory sequence within a single mRNA transcript, activating pattern-recognition receptors like RIG-I to trigger robust innate immune responses, enhancing antigen-specific immune responses without the need for separate adjuvants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate adjuvants are added to mRNA vaccines to enhance immune response, then immunogenicity is improved, but device complexity and off-target effects increase
Solution Approach 1:
The patent merges the antigen-coding mRNA and adjuvant sequences into a single integrated mRNA transcript. The adjuvant sequence is embedded within the mRNA molecule itself, eliminating the need for separate adjuvant components and complex delivery systems while maintaining enhanced immune response.
Solution Approach 2:
The mRNA molecule performs multiple functions simultaneously: it encodes the antigen protein and contains embedded adjuvant sequences that stimulate innate immunity. This multi-functional design simplifies the overall vaccine system by combining what were previously separate components into one universal molecule.
2Reliability
If separate adjuvants are used to stimulate innate immune system, then immune response is enhanced, but off-target effects occur
Solution Approach 1:
By combining the adjuvant sequence with the antigen mRNA into a single transcript, the patent ensures that the adjuvant is delivered only to cells that also receive and express the antigen. This co-delivery mechanism eliminates off-target effects by preventing adjuvant exposure in cells that do not express the target antigen.
Solution Approach 2:
The integrated mRNA transcript acts as an intermediary that couples antigen delivery with adjuvant delivery. The adjuvant sequence within the mRNA serves as a built-in mediator that activates innate immunity specifically in the context of antigen expression, ensuring targeted immune stimulation without systemic off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in increased immunogenicity, with enhanced type-I IFN responses and MHC class II expression, demonstrating broad efficacy in various cell types and viral antigens, improving antigen presentation and immune response without the drawbacks of traditional adjuvants.
Implementation Method 1
activating pattern-recognition receptors like RIG-I to trigger robust innate immune responses
Data Source
AI summary
Described herein are in vitro-transcribed (IVT) RNA molecules comprising, a 5′ cap structure, a coding region encoding an antigen polypeptide, an immunostimulatory RNA sequence, and a poly(A) tail.